Bio & Pharma
Prestige Bio's pancreatic cancer treatment gets US FDA fast-track designation
The S.Korean company intends to be reviewed sequentially following the receipt of data from clinical stages 1 and 2a
By Mar 16, 2023 (Gmt+09:00)
1
Min read
Most Read
Hankook Tire buys $1 bn Hanon Systems stake from Hahn & Co.
NPS to hike risky asset purchases under simplified allocation system
Osstem to buy Brazil’s No. 3 dental implant maker Implacil
S.Korea's LS Materials set to boost earnings ahead of IPO process
UAE to invest up to $1 bn in S.Korean ventures
Prestige Biopharma, a biopharmaceutical company in South Korea, announced on Thursday that their pancreatic cancer antibody drug, PBP1510 (Ulenistamab), has received fast-track designation from the US Food and Drug Administration.
This designation enables clinical development and application preparation for approval to proceed simultaneously, thereby shortening the time required for commercialization.
The company intends to be reviewed sequentially following the receipt of data from clinical stages 1 and 2a, which are currently underway in Europe and the US.
PBP1510 is a novel antibody drug that targets a protein found in pancreatic cancer. In 2020, it was granted orphan drug designation by both the US FDA and the Korean Ministry of Food and Drug Safety.
Write to Ji-Hyun Lee at bluesky@hankyung.com
More to Read
-
Bio & PharmaPrestige Bio's Herceptin biosimilar proves equivalence in clinical trials
Feb 08, 2023 (Gmt+09:00)
1 Min read -
Bio & PharmaPrestige Biopharma submits clinical trial plan in Australia
Feb 03, 2023 (Gmt+09:00)
1 Min read -
Bio & PharmaPrestige Biopharma attains patent for solid cancer treatment antibody
Jan 12, 2023 (Gmt+09:00)
1 Min read
Comment 0
LOG IN